<DOC>
	<DOCNO>NCT00148694</DOCNO>
	<brief_summary>The purpose study find effect preoperative therapy cisplatin patient early stage estrogen receptor-negative ( ER- ) , progesterone receptor-negative ( PR- ) , HER-2 negative breast cancer .</brief_summary>
	<brief_title>Preoperative Cisplatin Early Stage Breast Cancer</brief_title>
	<detailed_description>Before start treatment patient undergo placement clip tumor bed surgeon locate site tumor time surgery . Patients receive cisplatin intravenously every three week total 4 cycle 12 week treatment . After completion cisplatin , patient undergo surgery remove tumor remain assess tissue see tumor cell remain breast . Patients may receive second breast MRI biopsy 7-14 day treatment begin see whether identify tumor ultimately respond cisplatin rapid evaluation . Patients receive study treatment approximately 12 week unless unacceptable toxicity occurs . After surgery patient receive standard adjuvant therapy base discussion physician . Follow-up progress occur several year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>All tumor must ER , PR HER2 negative . Age &gt; 18 year ECOG performance status less equal 1 Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Hemoglobin &gt; 9mm/dl Platelets &gt; 100,000/mm3 Creatinine &lt; 1.5mg/dl Glucose &lt; 200mg/dl Bilirubin &lt; 1.5 x upper limit normal ( ULN ) SGOT &lt; 3.0 x ULN Prior chemotherapy treatment Pregnant breastfeed woman History serious illness , medical psychiatric condition require medical management Uncontrolled infection Renal dysfunction Active severe cardiovascular pulmonary disease Peripheral neuropathy etiology exceeds grade 1 Prior history malignancy Uncontrolled diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cisplatin</keyword>
	<keyword>Early Stage Breast Cancer</keyword>
	<keyword>ER Negative Breast Cancer</keyword>
	<keyword>PR Negative Breast Cancer</keyword>
	<keyword>HER-2 Negative Breast Cancer</keyword>
</DOC>